Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Time to next treatment as a prognostic marker in patients with AL amyloidosis

Despina Fotiou • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Despina Fotiou, MD, PhD, University of Athens, Athens, Greece, comments on the impact of time to next treatment in AL amyloidosis, highlighting the importance of considering multiple parameters when making the decision to change treatment. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Despina Fotiou

1:58
Improving diagnosis in AL amyloidosis using surrogate organ tissues for biopsies
Despina Fotiou • 6 Sep 2022
2:34
The prognostic role of t(11;14) in patients with newly diagnosed AL amyloidosis
Despina Fotiou • 6 Sep 2022

Related Videos

2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
0:52
The unmet needs that remain for patients with systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:45
Continuity of care for patients with hematological predispositions to AML
Anupama Rao • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals